DICLOFENAC POTASSIUM 50 MG + PARACETAMOL 325 MG + SERRATIOPEPTIDASE 15 MG TABLETS comprise three active ingredients available in a planned oral solid-dose format, with Diclofenac Potassium, Paracetamol and Serratiopeptidase. Multicomponent pharmaceutical formulation development involves control of preformulation studies, excipient compatibility evaluation, homogenous blending and development of compression parameters to ensure consistency of the finished product. The presence of the enzyme derived component (Serratiopeptidase) lends a further package of considerations around appropriate handling and stability during product development. For pharmaceutical companies with a broad development range for a PCD Pharma Franchise, this combination can be structured into a range of pharmaceutical compositions according to predefined quality specifications.
Formation of a multi-component formulation incorporates Diclofenac Potassium 50 MG + Paracetamol 325 MG + Serratiopeptidase 15 MG tablets per the composition. The individual ingredients have diverse properties to facilitate selection of excipients, design of process conditions and control of physical characteristics.
Suitable pharmaceutical excipients can be selected based on the nature of the product being developed, such as diluents, binders, disintegrants, glidants and lubricants. Each excipient type is suitable for assessed function in the product in addition to being compatible with the active pharmaceutical ingredients.
Preformulation assessment can explore particle size characteristics, bulk density, flow properties, moisture levels and potential tableting behavior of individual ingredients. Compatibility testing of each active ingredient with the excipients under preliminary product processing conditions can also ensure safe introduction to the final formulation.
The aim is to generate a consistent matrix of the active pharmaceutical ingredients within a suitable strength of the tablet.
DICLOFENAC POTASSIUM 50 MG + PARACETAMOL 325 MG + SERRATIOPEPTIDASE 15 MG TABLETS are advanced formulations where potential variability in the raw materials used exists because of different quantities or physical differences such as particle size, density and flow characteristics.
Validated identification processes are initial quality assurance steps prior to considering process parameters of the manufacturing process. Where applicable, sieving or other particle size adjustments are useful to establish a common standard for handling and processing.
A specified order of ingredient addition may be decided in process development depending on nature and physical form of the ingredients. Pre-blending of certain components of the mixture can enable uniform distribution of the blend once the total formulation is generated.
Controlled blending conditions can be devised for each mix stage, including feed rate, mixture time, turning and blending vessel loading to help reduce variability. Screening for uniformity of the blend can be conducted through representative sampling to ensure uniformity before tableting.
Once the blending has been consistent at the specified in process specifications, the material can be transferred to a suitable filling and compression system. Control of compression settings should accommodate the physical properties and flow of the powder mixture generated during formulation.
Formulation attributes such as compression, height and working speed can influence the weight, physical parameters and friability of the final finished product. In process control can monitor the appearance, weight, variation in weight, hardness and friability of the final product. Development of the process considers all applicable aspects of the component Serratiopeptidase, such as stability and handling behavior.
Further, the product may have uncoated or coated aspects depending on the finalized formulation.
Regardless of the circumstances, the coating process requires a stabilized formulation. The properties of the coating dispensation, spray rate, treatment temperature and effects on finished product uniformity can be carefully monitored to ensure a standard finished product.
Strength in the past, machine designed speeds and possible compression effects require balancing to generate a reproducible finished state. In addition to the physical attributes, dissolution characteristics, active strength and other relevant parameters can be monitored as part of the product functionality. The following steps include confirming the presence of the individual components through quantitative methodologies and the finished product through physical characteristics such as hardness, weight variation and appearance. In addition, a reference for the end point of the formulation and the product specifications are representative of the reputation of the company and support a diversified pharmaceutical portfolio.
Testing for quality control of a combination of three active pharmaceutical ingredients encompasses thorough testing of each as well as the finished product. Defined analytical procedures allow for the performance of compositional analysis for each ingredient, thus ensuring they fit within the range of specification. In case of a Serratiopeptidase bulk sample, appropriate analytical protocols or activity related methods can be established.
Physical characteristics of the finished product encompass weight variation, appearance, friability, and hardness. Disintegration and dissolution can also confirm the release properties of the product after introducing the ingredient. Dose unit uniformity testing for the individual components as well as the final formulation allows analysis of consistency of the ingredients within defined limits.
Assay and degradation trials within overall product specifications form part of the stability protocols, which are conducted at select time points across the shelf life of the product.
The assay includes quantification of each component (via validated methods) within the fully formulated tablet, along with physical parameters.
Stability assessment is an integral facet of the product development of DICLOFENAC POTASSIUM 50 MG + PARACETAMOL 325 MG + SERRATIOPEPTIDASE 15 MG Tablet. Stability studies should be directed to the attributes of all three active ingredients, the blend itself and the finished product. Monitoring of physical and compositional stability at specified intervals assesses the impact of storage conditions.
Selection of packaging is driven by the stability profile and each individual component. Suitable pharmaceutical packaging systems include blister packs, strip packs, bottle packs or other pharmaceutical-grade packaging configurations based on the product stability. For moisture-sensitive combinations, packaging can include bagging or unit dose packs that provide barrier protection against moisture ingress. Packaging integrity and compatibility between ingredients and the packaging system should be evaluated during the product development.
The packaging design can ensure ease of handling at the consumer level as well as indicating storage conditions. The product design considers batch size, packaging location and individual shelf life according to the goal of the final formulation.
In the context of a comprehensive pharmaceutical portfolio, DICLOFENAC POTASSIUM 50 MG + PARACETAMOL 325 MG + SERRATIOPEPTIDASE 15 MG Tablets can sit with a matrix of other combination, capsule, injectable and topical compositions. Adherence to a common set of specifications and packaging streamlines the management of the portfolio.
For a PCD Pharma Franchise portfolio, the finished formulation can be represented as a composition with clear details of its formulation, potential packaging matrix and authentic manufacturing unit details, as well as other permitted particulars and product information. Concise and uniform product documentation, together with consistent packaging content helps to rationalize a portfolio of the pharmaceutical range.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech